Focused On-demand Library for Cilium assembly protein DZIP1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q86YF9

UPID:

DZIP1_HUMAN

Alternative names:

DAZ-interacting protein 1/2; DAZ-interacting zinc finger protein 1

Alternative UPACC:

Q86YF9; Q5W078; Q5W079; Q8WY45; Q8WY46; Q9UGA5; Q9Y2K0

Background:

Cilium assembly protein DZIP1, also known as DAZ-interacting protein 1/2 and DAZ-interacting zinc finger protein 1, plays a pivotal role in cilium assembly and function. It acts as a molecular adapter, recruiting protein complexes essential for cilium biogenesis to the cilium basal body. DZIP1 is crucial for spermatogenesis, heart development, and Hedgehog signaling regulation through its involvement in ciliogenesis and protein transport to the cilium.

Therapeutic significance:

DZIP1's association with Mitral valve prolapse 3 and Spermatogenic failure 47 highlights its therapeutic potential. Understanding the role of Cilium assembly protein DZIP1 could open doors to potential therapeutic strategies for these conditions, emphasizing the importance of targeted research in uncovering novel treatment avenues.